VALUE MESSAGES​

PRIORITY

ASPIRATIONAL

KNOWN

KNOWN

EVIDENCE

ACTIVITIES

In patients with DH, DHB311 demonstrated acceptable safety comparable to placebo

1

1

In patients with DH, DHB311 demonstrated acceptable safety comparable to placebo

1

2

DHB311 treatment results in a durable reduction of vomiting.

2

1

DHB311 significantly improves patient experience of core symptoms of DH, including nausea, abdominal pain, post-prandial fullness and bloating vs. placebo.

0

2

There is a significant unmet need for DH treatments that can effectively relieve debilitating symptoms of the disease, decrease use of healthcare services and improve patient productivity.

1

1

DH patients have an average of 1-2 hospitalizations / year at $15K - 25K / hospitalization.

1

1

QoL impairment combined with limited treatment options often lead to an increased use of ER and hospital services.

0

1

DH is often underrecognized and undiagnosed until complications arise.

0

1

While a clear consensus regarding the definition of DH does not exist, DH research estimates it affects 15% to 40% of diabetes population.

0

1

Diabetes affects 382 million adults worldwide. The affected population is increasing and is expected to grow to 443 million by 2025.

0

1